Exhibition

EG-R mRNA Delivery System

EG-R mRNA Delivery System

EG-R can be used for an mRNA delivery carrier.


Negotiable Min Order Quantity Unit

Required Quantity
Place of Origin
South Korea
Brand name
EG-R mRNA Delivery System
Payment Terms
Others
Production method
Available
Shipping / Lead Time
Negotiable / Negotiable
Keyword
lyophilization, mrna, liposome, delivery system
Category
Medicines , Other Pharmaceuticals , Pharmaceutical Intermediates
tK Meet
tK Meet

Apply a video call to the Supplier

SEND TO SUPPLIER INQUIRY

EYEGENE Inc.

Membership
VIP
Country / Year Established
South Korea South Korea / 2000
Business type
Others
Verified Certificate

2

DUNS

Product name EG-R mRNA Delivery System Certification -
Category Medicines
Other Pharmaceuticals
Pharmaceutical Intermediates
Material CATIONIC LIPOSOME
Keyword lyophilization , mrna , liposome , delivery system Unit Size -
Brand name EG-R mRNA Delivery System Unit Weigh -
origin South Korea Stock 1
Supply type Available HS code -

Product Information

A liposome is a spherical-shaped vesicle that is composed of phospholipid bilayers, which closely resembles the structure of cell membranes, and exhibited biocompatibility and biodegradability.

 

Liposomes have long been used as drug delivery or adjuvant for human vaccine. Here, we suggested novel cationic liposome-based mRNA delivery systems called EG-R. EG-R are composed of a cationic lipid, 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and helper lipid.

 

EG-R can be used for an mRNA delivery carrier. Complexes of Renilla luciferase mRNA and EG-R were intramuscularly injected into mice and observed that the expression of Renilla luciferase was successfully achieved.

 

Moreover, we prepared a lyophilized form of Renilla luciferase mRNA and EG-R complex and confirmed that the lyophilized form is likely deliver mRNA as efficient as liquid form. Taken together, we suggested the EG-R is efficient mRNA delivery system for various type of mRNA vaccines.

 

<EG-R can be prepared as a freeze-dried (lyophiliztion) form>

▶Freeze-dried ER-G overcomes many hurdles in vaccine equity through the use of a simple household refrigator (no expensive cryogenic system required)

 

▶ Conveniently transported, managed and administered with a long shelf life

 

▶ Relatively inexpensive to distribute to low-income countries 

 

1. Delivery Efficiency

▶EG-R lipolex observed that the locally expression of Renilla luciferase was successfully achieved.

 

2. East to Applicate

▶ EG-R lipolex can be applicated infectious disease, Therapeutics for OA and Cancer Vaccines.

 

3. Biodistribution of EG-R system

▶EG-R lipoplex was observed localized expression pattern of biodistribution.

 

4. Safety Profile

▶Suspicions grow that nanoparticle(LNP) in some COVID-19 vaccine trigger rare allergic reactions due to PEG hypersensitivity.

▶No issue with Toxicology result.

 

5. Preclinical Efficacy Profile

▶EG-R demonstrated humoral immunity, CMI and Neutralization activity for SARS-COV-2 WT.

 

6. Stability at 4

▶Lyophilized EG-R lipoplexes at 4℃ for up to 8 weeks show no change in physical characteristics.

 

7. Long-Term Stabiligy of DP at 4

▶The mRNA vaccine complexed with EG-R, DP(EG-COVID) is proved to be very stable stored at 2-8℃ up to 6 months.


 

 

Product Info Attached File

(B)RTX220316_EG-R Brochure_Eyegene.pdf

B2B Trade

Price (FOB) Negotiable transportation Negotiation Other
MOQ Negotiable Leadtime Negotiable
Payment Options Others Shipping time Negotiable

EYEGENE Inc.

Country / Year Established
South Korea South Korea / 2000
Membership
VIP
Business type
Others

2

DUNS

President
Wonil Yoo
Address
b-910, 401 Yangcheon-ro, Gangseo-gu, Seoul, Korea
Product Category
Other Chemicals
Year Established
2000
No. of Total Employees
51-100
Company introduction

Eyegene took its first step in the development of innovative biopharmaceutical drugs when it was first established in june 2020.

Since then, Eyegene has continued to research and develop innovative drugs to overcome the deterioration of the quality of life due to aging.

 

Eyegene has two core technologies. EGT022 os a molecule for the treatment of ischemic diseases based on proteomic research. It is being developed as a treatment for diabetic retinopathy, pressure ulcers, wound healing, and Myocardial ischemia/Reperfusion Injury. Various Premium Vaccines for adults are also being developed using Eyegene's proprietary Adjuvant, which has been established through continuous research in the field of immunology. 

 

Main Markets

Argentina Argentina

Brazil Brazil

India India

Indonesia Indonesia

Viet Nam Viet Nam

Main Product
Attached File

Related Products

Other buyers also search

Membership Grade

BUYER

Biz Pro VIP

SELLER

Biz Pro VIP
팝업닫기
Live Chat A new message arrives
from a business partner.

No Data

  • There is no data to load
  • Check out the My tK > My Inquiries list.
  • After agreeing to the use of the Live Chat service, the list is printed only when there is at least one history of receiving or sending a Live Chat request.

If you have not yet agreed to use the Live Chat service,

You can use the Live Chat freely after agreeing to the use of the Live Chat service.

View more
View more